Leslie Leinwand - MyoKardia Insider

MYOK -- USA Stock  

USD 56.80  1.15  2.07%

We currently do not have informatin regarding Leslie Leinwand. This executive tanure with MyoKardia is not currenlty determined.
650-741-0900  http://www.myokardia.com

Management Efficiency

The company has return on total asset (ROA) of (14.21) % which means that it has lost $14.21 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (27.81) % meaning that it created substantial loss on money invested by shareholders.

Entity Summary

MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of rare cardiovascular diseases. MyoKardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California. MyoKardia operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 120 people.MyoKardia (MYOK) is traded on BATS Exchange in USA. It is located in CALIFORNIA U.S.A and employs 120 people. MyoKardia is listed under Pharmaceutical Products category by Fama And French industry classification.

MyoKardia Leadership Team

Eric Topol, Independent Director
Sunil Agarwal, Independent Director
Christine MD, Co-Founder
Taylor Harris, CFO
Mark Perry, Independent Director
June Lee, COO
Wendy Yarno, Independent Director
Kevin Starr, Director
Jake Bauer, Vice President - Business Development and Business Operations
Joseph Lambing, Senior Vice President - Nonclinical and Pharmaceutical Development
Steven Chan, Vice President Corporate Controller
Mary Cranston, Director
Katherine Bowdish, Director
Robert McDowell, Sr. VP of Drug Discovery
David Meeker, Independent Director
Marc Semigran, Chief Medical Officer
Leslie Leinwand, Co-Founder
Tassos Gianakakos, CEO and President and Director
Charles Homcy, Director
Jonathan Fox, Chief Medical Officer
Kimberly Popovits, Independent Director

Stock Performance Indicators

Current Sentiment - MYOK

MyoKardia Investor Sentiment
Most of Macroaxis users are now bullish on MyoKardia. What is your trading attitude regarding investing in MyoKardia? Are you bullish or bearish?
98% Bullish
2% Bearish

Build Optimal Portfolios

Align your risk with return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. drill down to check world indexes.